ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

NCAB Says President’s Budget Would “Seriously Damage” Cancer Program

February 12, 1999

DCE Board Oks Concept For Three Contracts In Radiation Epidemiology

June 29, 1984

ICCCR Issues RFP For Cancer Risk Scale

March 6, 1992

DCPC Board Commits More Than $100 Million To 15-Year Trial Of Low Fat Diet In Women

October 26, 1990

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

February 12, 1999

FDA Expands Nexavar Indication To Include Thyroid Cancer

December 27, 2013